Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We're back to dreaming of a Fortune 500 White Knight.
Can't help feeling misled by Bunka, by in a May interview he bemoaned the fact that Altria hadn't made a decision yet despite them receiving the last scientific nicotine study on April 15. If he had read the contract he signed with Altria he must of known that they had 90 days to review the info, and then another 90 days before they had to decide to invest a further tranche yet he didn't tell us this. Hurry up and wait for R/S!
I have no doubt that Altria will drag it out for another 90 days, I'm disappointed again.
We are, and they aren't!
Tuesdays are good days for news releases. It's time for Altria to disclose their insidious plan to addict the world to nicotine using oral formulations powered by DehydraTECH.
Altria has exclusive US rights but has non-exclusive rights for the rest of the world. The deal is not dead.
Here's how much Covid-19 drug remdesivir will cost
From CNN's Jacqueline Howard and Naomi Thomas
Gilead Sciences, the company that makes Covid-19 drug remdesivir, announced in an open letter this morning that it has decided to set a price of $390 per vial for the US government, which would include Medicaid, and for the governments of developed countries.
A typical five-day treatment course would include six vials, which would equate to $2,340 per patient, Daniel O'Day, Gilead Sciences chairman and CEO, said in the letter. The US government will continue to manage US allocations of remdesivir to hospitals through September, the company said.
The letter added that the price for US private insurance companies will be $520 per vial, which adds up to $3,120 per patient for a five-day treatment course of six vials.
"As with all our actions on remdesivir, we approached this with the aim of helping as many patients as possible, as quickly as possible and in the most responsible way. This has been our compass point throughout, from collaborating to find rapid answers on safety and efficacy, to scaling up manufacturing and donating our supply of remdesivir through the end of June. In each case, we recognized the need to do things differently to reflect the exceptional circumstances of the pandemic. Now, as we transition beyond the donation period and set a price for remdesivir, the same principle applies," O'Day said in the letter.
About the drug: Remdesivir, which is currently administered intravenously through infusions, is the only drug that has an emergency use authorization from the US Food and Drug Administration to treat coronavirus infections.
Until now, remdesivir treatments had been donated to the US government and allocated by the US Department of Health and Human Services and states. However, the US government’s last scheduled shipments of that donation are going out today.
"At the level we have priced remdesivir and with government programs in place, along with additional Gilead assistance as needed, we believe all patients will have access," O'Day said. "Gilead has entered into an agreement with the U.S. Department of Health and Human Services (HHS) whereby HHS and states will continue to manage allocation to hospitals until the end of September. After this period, once supplies are less constrained, HHS will no longer manage allocation."
HHS Secretary Alex Azar announced that agreement during an appearance on “Good Morning America” on Monday.
"President Trump has secured half a million courses of treatment of remdesivir through September," Azar told ABC's George Stephanopoulos.
The ingredient list for Canopy Growth's Houndstooth and Soda cannabis beverage.
Carbonated water, Distilled cannabis terpene blend (vegetable glycerin, monoglyceride, soy lecithin, sucrose monopalmitate, cannabis distillate, cannabis terpenes), calcium disodium EDTA, potassium citrate, natural flavoring.
They're not using a full-spectrum cannabis oil, terpenes are added back in. It's not all-natural, chemical emulsifiers are used. It's not sugar-free, sugar and flavorings are used to hide the taste of cannabis. Only 3 calories per can though. I wonder what the shelf-life is and whether the cannabis bonds to the liner of the cans?
I asked management about vaccines during their last webinar, they said that it was a possibility but it wasn't their focus at the moment.
All-in-all it's a well-written pump. We seem to have acquired a better IR group. Network Newswire sucked.
Outrageous BS: "being licensed by billion-dollar companies across a broad range of sectors."
If this was true we sure wouldn't be doing a R/S.
I wonder if DehydraTECH works on animals, has there been any studies?
https://420intel.com/articles/2020/06/24/martha-stewarts-cbd-pets-brand-expected-hit-markets-fall#.XvNtVurlf5g.facebook
The Entourage Effect is another reason we should rise to the top. Virtually everybody except Lexy is using an isolate or distillate for beverages and edibles and thus are not full-spectrum.
Dr. Ethan Russo on the Entourage Effect
Dr. Ethan Russo is a neurologist who currently serves as the Director of Research and Development at the International Cannabis and Cannabinoids Institute in Prague.
In a 2019 interview, Russo redefined the phrase “entourage effect” from a scientific perspective, attempting to convey the significance and complexity of botanical synergy:
“A botanical doesn’t rely on one compound to produce the beneficial effects. Rather there may be many — and that’s certainly the case in cannabis where we know that there are actually over one-hundred related molecules, which we call cannabinoids, but in addition, there are aromatic compounds [called] terpenoids that alter the effects of the cannabinoids in a way that often is synergistic. Synergy is a boosting of effect. So, it would be the idea that 2 + 2, instead of equaling 4, gives you an 8 in terms of the benefit. . . .It is sort of like an ensemble of musical instruments where you might think of THC as the soloist with an important part provided by cannabidiol, but you also have these other components producing a harmony that really increases the overall effect…” (“Dr Ethan Russo: CBD, The Entourage Effect, and the MicroBiome”, 2019)
Tinley Beverage has beaten the problem of cannabis bonding to plastic by using all glass bottles. Not sure of the shelf life. Tinley uses nano-emulsification technology from Vertosa and they are using a distillate so their products do not contain full-spectrum cannabinoids unlike Lexy.
https://vertosa.com/news-and-updates/2019/10/4/will-infused-drinks-change-how-we-consume-cannabis
This is all very interesting because I believe that Health Canada will be all over this PDQ. There will be product recalls because of ingredient quality and probably a future requirement for proper safety testing of Cannabis-infused products. Safety testing like Lexaria has already completed at the National Research Council of Canada.
Perhaps our day-in-the sun is coming sooner than we expect.
Could this help Lexy? This is an ongoing problem that seems to be that the cannabinoids bond to any plastic in the container and it's especially bad with aluminum cans that have a thin plastic liner. Chris Bunks claims this doesn't happen with DehydraTECH.
https://cannabislaw.report/aurora-tilray-other-canadian-cannabis-companies-sued-for-selling-cannabis-product-with-false-potency-levels/
Thanks, I'll give it a try.
Who did you ask Lexaria or the US distributor?
That's not totally true I did manage to try the Vipova tea, it came across the border somehow. Great tasting CBD tea!
It would at least be nice for a Canadian shareholder like myself to be able to try Lexaria's products. I've been a shareholder for years now, yet I have been unable to try the products the company I've invested in makes, and that is frustrating.
There's another timeline we're not sure about, when will Hill Street get their HC licenses. Even if these licenses are forthcoming I doubt if Hill Street can get any products to market before Spring 2021. I don't give any value to this deal at all, presently.
I've been eagerly awaiting news about this anti-viral program but there doesn't appear to be much new here.
I had hoped that this program would be fast-tracked and preliminary results would be out quickly but that doesn't appear to be the case as we're still waiting for approval before the study can begin. One can only wonder what the timeline on this process will be.
"Lexaria intends to conduct this first study at a leading Canadian university where a study design and plan has already been submitted for ethics board approval. Lexaria will provide further details upon successful conclusion of the review process, as well as study outcomes when available."
https://www.lexariabioscience.com/news/lexaria-bioscience-begins-coronavirus-covid-19-drug-delivery-program/
The price they finally pay for Lexaria Nicotine depends on the value of nicotine product sales using DehydraTECH, so expect 2 years of sales after product development to determine a true value for L.N.
No, I don't think that at all. That's an unfounded conspiracy theory, IMO.
Another 30 days is my understanding, Altria didn't get the final documents until April 15, so 90 days from then.
Great info thanks for posting.
Here's what's in an On! pouch now: Nicotine Bitartrate Dihydrate, Microcrystalline Cellulose, Flavors, Sodium Carbonates, Binders.
If the use of DehydraTECH can eliminate the need for some of these pH adjusters, sweeteners, flavorings, fillers and stabilizers then perhaps we can lower the cost, along with better performance.
My point is that DehydraTECH delivers more nicotine across the blood-brain barrier so you get more effect with less nicotine but you would only have to take the On! pouch with a higher nicotine content to get the same effect so does DehydraTECH really show an advantage in pouches? I'm talking about normal doses of nicotine which an individual would take on a daily basis, not high doses that would cause side effects.
That will definitely be one product, powdered nicotine packets, just pour one into your coffee while you're on your way to your yearly performance evaluation, or add it to your beer because you can't stand going outside to smoke in whatever weather. etc. etc.
True, but I'm not sure DehydraTECH is going to improve the On! pouches that much or if Altria will even use it in that application. The pouches rely on mucosal absorption to get the nicotine into the bloodstream, which is very quick, so there doesn't seem to be a need for Lexy's tech. Someone will point out to me that DehydraTECH will increase the amount of nicotine that crosses the blood-brain barrier but if you want a more intense effect then you could just take the higher dose On! pouch. Then, of course, there are the cost savings from using less nicotine but will the savings really be substantial when nicotine is readily available and reasonably priced commercially.
I see Lexy's tech being used in a new class of orally ingestible nicotine products. Like Red Bull.
That's good. Now that the mountain of paperwork is out of the way, maybe Altria can turn their attention to Little Lexy?
Yeah, I noticed that. I don't know why their website is out of date in that respect, maybe the analysis is still fundamentally the same?
Lexaria's logo is still on their website, at the end, so they must still be Lexaria people.
They used to have "Powered by Lexaria" on the cans, now nothing. Are they still using Lexaria's tech?
https://cdn.shopify.com/s/files/1/0010/5123/0267/files/Cannadips_America_CBD-C1809009-01A_-_9-17-2018.pdf?591720512686978568
I think Lexy might have already dumped Network News Wire, you don't see them rewriting Lexy's news releases anymore.
https://www.cnn.com/2020/06/01/health/remdesivir-coronavirus-phase-iii-trial-gilead-study/index.html
(CNN)A five-day course of the antiviral drug remdesivir sped recovery in moderately ill patients with pneumonia from Covid-19, drugmaker Gilead Sciences announced in a statement Monday.
It's more evidence that the drug can help patients, however outside experts are not calling this a "game changer" quite yet.
Coronavirus patients who were hospitalized, but not sick enough to need oxygen from a ventilator, were more likely to recover after a five-day course of remdesivir than those given the current standard of care alone, Gilead said.
Hospitals frustrated by remdesivir supply
Hospitals frustrated by remdesivir supply 02:30
The results from the Phase III clinical trial on the drug have not yet been published in a peer-reviewed medical journal. Gilead said it plans to submit the full data for publication in the coming weeks.
In Cod We Trust
Tommy Cod Foolery!
That's it thanks Stockman, I'm going to self-medicate against the virus right now. Death Bubba distillate pen where are you?